Soleno Therapeutics (SLNO) remains unprofitable, with losses deepening at an annual rate of 43.6% over the past five years. However, analysts now forecast profitability within the next three years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback